Citation Impact
Citing Papers
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
2000 Standout
Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study
2011 Standout
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
2004 StandoutScience
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
2013 Standout
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
2008 Standout
Metastasis: from dissemination to organ-specific colonization
2009 Standout
Estimating the mean and variance from the median, range, and the size of a sample
2005 Standout
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
2004 Standout
Multidrug resistance in cancer: role of ATP–dependent transporters
2002 Standout
Comparative epidemiologic study of premalignant and malignant epithelial cutaneous lesions developing after kidney and heart transplantation
1995
Cancer immunoediting: from immunosurveillance to tumor escape
2002 Standout
Current State of Preeclampsia Mouse Models: Approaches, Relevance, and Standardization
2021
EGFR Antagonists in Cancer Treatment
2008 Standout
Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.
1994
Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy
1999
Myasthenia Gravis
2016 Standout
A brief review of recent data on some cytokine expressions at the materno-foetal interface which might challenge the classical Th1/Th2 dichotomy
2002
Transfusion Strategies for Acute Upper Gastrointestinal Bleeding
2013 Standout
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 Standout
Aids-related malignancies
2002
Chemotherapy vs Supportive Care in Advanced Non-Small-Cell Lung Cancer
1994
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594
2001
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
2014 Standout
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party.
1995
Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study.
1998
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
2007 StandoutNature
Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience.
1991
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
2006 Standout
Lung cancer: New biological insights and recent therapeutic advances
2011
Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
2010 Standout
New drugs in the treatment of non-small cell lung cancer
1995
Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial
1998
Skin Cancers after Organ Transplantation
2003 Standout
Mechanisms of T cell tolerance towards the allogeneic fetus
2012
Lung cancer: current therapies and new targeted treatments
2016 Standout
ErbBs in lung cancer
2008
Targeting multidrug resistance in cancer
2006 Standout
Treatment Paradigms for Patients with Metastatic Non-Small Cell Lung Cancer, Squamous Lung Cancer: First, Second, and Third-Line
2014
A molecular signature of metastasis in primary solid tumors
2002 Standout
Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor Dimerization
2012 StandoutNobel
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
2016 Standout
Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin–vindesine
2001
A Randomized Trial of Induction Chemotherapy plus High-Dose Radiation versus Radiation Alone in Stage III Non-Small-Cell Lung Cancer
1990
Second-Line Chemotherapy with 96-Hour Infusional Paclitaxel in Refractory Non-Small Cell Lung Cancer: Report of a Phase II Trial
1999
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
2005 Standout
Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.
1995
Epstein–Barr virus: 40 years on
2004 Standout
Myasthenia gravis: management issues during pregnancy
2005
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
2016 Standout
The Th2 Cytokine Environment of the Placenta
2000
New chemotherapy agents in the treatment of advanced non-small cell lung cancer: An update including data from the seventh world conference on lung cancer
1995
Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group.
1993
Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer
2011
Paradoxical roles of the immune system during cancer development
2006 Standout
Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer
2001
Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer
1995
A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC)
2000
Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study
1993
Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy?
2001
Transfusion-related immunomodulation (TRIM): An update
2007
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
2005 Standout
Liposomal drug delivery systems: From concept to clinical applications
2012 Standout
Removing the Vertebrate-Specific TBP N Terminus Disrupts Placental β2m-Dependent Interactions with the Maternal Immune System
2002 StandoutNobel
Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer.
1995
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
2002 Standout
Phase I study of vinorelbine, cisplatin, and concomitant thoracic radiation in the treatment of advanced chest malignancies.
1998
Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?
1993
Alternative activation of macrophages
2003 Standout
Gemcitabine
1997
Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group.
1989
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
2004 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Ionizable Lipid Nanoparticles for In Vivo mRNA Delivery to the Placenta during Pregnancy
2023 StandoutNobel
Duration of Chemotherapy in Advanced Non–Small-Cell Lung Cancer: A Randomized Trial of Three Versus Six Courses of Mitomycin, Vinblastine, and Cisplatin
2001
Orthogonal Design of Experiments for Engineering of Lipid Nanoparticles for mRNA Delivery to the Placenta
2023 StandoutNobel
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
Tumour stem cells and drug resistance
2005 Standout
Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer
2000
Dendritic Cells Initiate Immune Control of Epstein-Barr Virus Transformation of B Lymphocytes In Vitro
2003 StandoutNobel
Chemotherapy of advanced non-small cell lung cancer
1999
Mitomycin, Ifosfamide, and Cisplatin in Unresectable Non–Small-Cell Lung Cancer: Effects on Survival and Quality of Life
1999
Twenty-Two Years of Phase III Trials for Patients With Advanced Non–Small-Cell Lung Cancer: Sobering Results
2001
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
2004 Standout
Long Term Analysis of Survival in the European Randomized Trial Comparing Vinorelbine/Cisplatin to Vindesine/Cisplatin and Vinorelbine Alone in Advanced Non-Small Cell Lung Cancer
2001
Cancer Genome Landscapes
2013 StandoutScience
Extrathymic Development of Vα11 T Cells in Placenta During Pregnancy and Their Possible Physiological Role
2001
Impact of the Placental Cytokine-Chemokine Balance on Regulation of Cell-Cell Contact-Induced Human Immunodeficiency Virus Type 1 Translocation across a Trophoblastic Barrier In Vitro
2005 StandoutNobel
Preterm labor: One syndrome, many causes
2014 StandoutScience
Soluble Fibrinogen-Like Protein 2/Fibroleukin Exhibits Immunosuppressive Properties: Suppressing T Cell Proliferation and Inhibiting Maturation of Bone Marrow-Derived Dendritic Cells
2003
Trends in the Aggressiveness of Cancer Care Near the End of Life
2004 Standout
Second-line chemotherapy for non-small cell lung cancer
2002
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Works of DavidA. Clark being referenced
The fgl2 prothrombinase/fibroleukin gene is required for lipopolysaccharide-triggered abortions and for normal mouse reproduction
2004
Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.
1988
Treatment of antenatal myasthenia gravis.
1991
Cytokine-dependent abortion in CBA x DBA/2 mice is mediated by the procoagulant fgl2 prothrombinase [correction of prothombinase].
1998
Treatment of Antenatal Myasthenia Gravis
1992
SKIN CANCER AND IMMUNOSUPPRESSION
1972